Tag Archives: biobucks

Earnout payments have been nearly ubiquitous in biotech M&A transactions for the past decade. Given the risks, costs, and timelines in drug R&D, these contingent value rights, or “biobucks”, play an important role in bridging the gap in valuation expectations

Milestone payments are an important risk-sharing component in today’s biopharma deal-making toolbox. As it’s a topic I’ve explored in the past (here, here), it’s an opportune time to revisit the stats for how they have performed recently. These contingent value transfers